Jiaolin Zhou1, Huizhong Qiu2, Guole Lin1, Yi Xiao1, Bin Wu1, Wenming Wu1, Xiyu Sun1, Junyang Lu1, Guannan Zhang1, Lai Xu1, Yuchao Liu1. 1. Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Dong Dan, Dong Cheng District, Beijing, 100730, China. 2. Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Dong Dan, Dong Cheng District, Beijing, 100730, China. qiuhzpumch@163.com.
Abstract
OBJECTIVES: According to practice guidelines, adjuvant chemotherapy (ACT) is required for all patients with locally advanced rectal cancer who have received neoadjuvant chemoradiotherapy (NCRT) and total mesorectal excision (TME). The objective of this study was to determine whether ACT is necessary for patients achieving pathological complete response (pCR) after NCRT followed by surgery. METHODS: By retrospectively reviewing a prospectively collected database in our single tertiary care center, 210 patients with locally advanced rectal cancer who underwent NCRT followed by TME were identified between February 2005 and August 2013. All patients achieving ypCR were enrolled in this study, in which who underwent ACT (chemo group) and who did not (non-chemo group) were compared in terms of local recurrence (LR) rate, 5-year disease-free survival (DFS) rate and overall survival (OS) rate. RESULTS: Forty consecutive patients with ypCR were enrolled, 19 (47.5 %) in chemo group and 21 (52.5 %) in non-chemo group. After a median follow-up of 57 months, five patients developed systemic recurrences, with the 5y-DFS rate of 83.5 %. No LR occurred in the two groups. The 5y-DFS rates for patients in chemo group and non-chemo group was 90.9 and 76.0 %, respectively, showing no statistically significant difference (p = 0.142). Multivariate analysis showed that tumor grade was the only independent prognostic factor for 5y-DFS and 5y-OS. CONCLUSIONS: Results of this study suggested that it may not be necessary for all rectal cancer patients with ypCR after NCRT and radical surgery to receive ACT. Prospective randomized trials are warranted to further determine the value of ACT for ypCR patients.
OBJECTIVES: According to practice guidelines, adjuvant chemotherapy (ACT) is required for all patients with locally advanced rectal cancer who have received neoadjuvant chemoradiotherapy (NCRT) and total mesorectal excision (TME). The objective of this study was to determine whether ACT is necessary for patients achieving pathological complete response (pCR) after NCRT followed by surgery. METHODS: By retrospectively reviewing a prospectively collected database in our single tertiary care center, 210 patients with locally advanced rectal cancer who underwent NCRT followed by TME were identified between February 2005 and August 2013. All patients achieving ypCR were enrolled in this study, in which who underwent ACT (chemo group) and who did not (non-chemo group) were compared in terms of local recurrence (LR) rate, 5-year disease-free survival (DFS) rate and overall survival (OS) rate. RESULTS: Forty consecutive patients with ypCR were enrolled, 19 (47.5 %) in chemo group and 21 (52.5 %) in non-chemo group. After a median follow-up of 57 months, five patients developed systemic recurrences, with the 5y-DFS rate of 83.5 %. No LR occurred in the two groups. The 5y-DFS rates for patients in chemo group and non-chemo group was 90.9 and 76.0 %, respectively, showing no statistically significant difference (p = 0.142). Multivariate analysis showed that tumor grade was the only independent prognostic factor for 5y-DFS and 5y-OS. CONCLUSIONS: Results of this study suggested that it may not be necessary for all rectal cancerpatients with ypCR after NCRT and radical surgery to receive ACT. Prospective randomized trials are warranted to further determine the value of ACT for ypCR patients.
Authors: Carlo Capirci; Vincenzo Valentini; Luca Cionini; Antonino De Paoli; Claus Rodel; Robert Glynne-Jones; Claudio Coco; Mario Romano; Giovanna Mantello; Silvia Palazzi; Falchetti Osti Mattia; Maria Luisa Friso; Domenico Genovesi; Cristiana Vidali; Maria Antonietta Gambacorta; Alberto Buffoli; Marco Lupattelli; Maria Silvia Favretto; Giuseppe La Torre Journal: Int J Radiat Oncol Biol Phys Date: 2008-04-11 Impact factor: 7.038
Authors: Anne J Breugom; Marloes Swets; Jean-François Bosset; Laurence Collette; Aldo Sainato; Luca Cionini; Rob Glynne-Jones; Nicholas Counsell; Esther Bastiaannet; Colette B M van den Broek; Gerrit-Jan Liefers; Hein Putter; Cornelis J H van de Velde Journal: Lancet Oncol Date: 2015-01-12 Impact factor: 41.316
Authors: Al B Benson; Tanios Bekaii-Saab; Emily Chan; Yi-Jen Chen; Michael A Choti; Harry S Cooper; Paul F Engstrom; Peter C Enzinger; Marwan G Fakih; Charles S Fuchs; Jean L Grem; Steven Hunt; Lucille A Leong; Edward Lin; Michael G Martin; Kilian Salerno May; Mary F Mulcahy; Kate Murphy; Eric Rohren; David P Ryan; Leonard Saltz; Sunil Sharma; David Shibata; John M Skibber; William Small; Constantinos T Sofocleous; Alan P Venook; Christopher G Willett; Deborah A Freedman-Cass; Kristina M Gregory Journal: J Natl Compr Canc Netw Date: 2012-12-01 Impact factor: 11.908
Authors: Alfonso De Stefano; Roberto Moretto; Luigi Bucci; Stefano Pepe; Francesco Jacopo Romano; Alessandra Chiara Cella; Laura Attademo; Mario Rosanova; Stefano De Falco; Giovanni Fiore; Lucia Raimondo; Sabino De Placido; Chiara Carlomagno Journal: Clin Colorectal Cancer Date: 2014-06-26 Impact factor: 4.481
Authors: Fahima Dossa; Sergio A Acuna; Aaron S Rickles; Mariana Berho; Steven D Wexner; Fayez A Quereshy; Nancy N Baxter; Sami A Chadi Journal: JAMA Oncol Date: 2018-07-01 Impact factor: 31.777